Skip to main content

Table 4 GRADE evidence profile for effectiveness of influenza vaccination in patients with end-stage renal disease

From: Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety

Quality assessment

No of patients

Effect

Quality

Importance

No of studies

Design

Risk of bias

Inconsistency

Indirectness

Imprecision

Other considerations

Vaccination against influenza

Control

Relative (95% CI)

Absolute

  

All-cause mortality

4

Observational studies

Serious1

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

1,798/8,759 (20.5%)2

RR 0.68 (0.61–0.76)3

66 fewer per 1,000 (from 49 fewer to 80 fewer)

⊕ΟΟΟ VERY LOW

CRITICAL

 

10%

32 fewer per 1,000 (from 24 fewer to 39 fewer)

 

40%

128 fewer per 1,000 (from 96 fewer to 156 fewer)

Cardiac death

1

Observational studies

Serious4

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

5%

RR 0.84 (0.71–0.98)5

8 fewer per 1,000 (from 1 fewer to 15 fewer)

⊕ΟΟΟ VERY LOW

CRITICAL

 

10%

16 fewer per 1,000 (from 2 fewer to 29 fewer)

 

20%

32 fewer per 1,000 (from 4 fewer to 58 fewer)

Infectious death

1

Observational studies

Serious4

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

5%

RR 0.83 (0.65–1.05)5

9 fewer per 1,000 (from 18 fewer to 2 more)

⊕ΟΟΟ VERY LOW

CRITICAL

 

10%

17 fewer per 1,000 (from 35 fewer to 5 more)

 

20%

34 fewer per 1,000 (from 70 fewer to 10 more)

All-cause hospitalization

2

Observational studies

Serious1

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

1,688/1,888 (89.4%)6

RR 0.88 (0.74–1.04)7

107 fewer per 1,000 (from 232 fewer to 36 more)

⊕ΟΟΟ VERY LOW

CRITICAL

 

20%

24 fewer per 1,000 (from 52 fewer to 8 more)

 

40%

48 fewer per 1,000 (from 104 fewer to 16 more)

Influenza/pneumonia hospitalization

4

Observational studies

Serious8

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

445/2,584 (17.2%)

RR 0.86 (0.8–0.93)3

24 fewer per 1,000 (from 12 fewer to 34 fewer)

⊕ΟΟΟ VERY LOW

CRITICAL

 

5%

7 fewer per 1,000 (from 3 fewer to 10 fewer)

 

30%

42 fewer per 1,000 (from 21 fewer to 60 fewer)

Hospitalization due to bacteremia, viremia or septicemia

1

Observational studies

Serious4

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

5%

RR 0.73 (0.32–1.68)5

13 fewer per 1,000 (from 34 fewer to 34 more)

⊕ΟΟΟ VERY LOW

CRITICAL

 

10%

27 fewer per 1,000 (from 68 fewer to 68 more)

 

20%

54 fewer per 1,000 (from 136 fewer to 136 more)

Hospitalization due to respiratory infection

1

Observational studies

Serious4

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

5%

RR 0.87 (0.69–1.09)5

6 fewer per 1,000 (from 16 fewer to 5 more)

⊕ΟΟΟ VERY LOW

CRITICAL

 

10%

13 fewer per 1,000 (from 31 fewer to 9 more)

 

20%

26 fewer per 1,000 (from 62 fewer to 18 more)

ICU admission

1

Observational studies

Serious9

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

184/2,696 (6.8%)

RR 0.19 (0.14–0.27)

55 fewer per 1,000 (from 50 fewer to 59 fewer)

⊕ΟΟΟ VERY LOW

CRITICAL

 

12%

97 fewer per 1,000 (from 88 fewer to 103 fewer)

 

25%

203 fewer per 1,000 (from 183 fewer to 215 fewer)

Influenza-like illness

1

Observational studies

Serious10

No serious inconsistency

No serious indirectness

No serious imprecision

None

–

5%

RR 0.88 (0.86–0.9)11

6 fewer per 1,000 (from 5 fewer to 7 fewer)

⊕ΟΟΟ VERY LOW

CRITICAL

 

10%

12 fewer per 1,000 (from 10 fewer to 14 fewer)

 

20%

24 fewer per 1,000 (from 20 fewer to 28 fewer)

  1. 1High risk of bias in two of four studies due to inappropriate adjustment for confounders and unclear baseline imbalance.
  2. 2Control group rates available in only two of four studies.
  3. 3RR adjusted in all four studies at least for age, sex, and comorbidities.
  4. 4High risk of bias due to missing information on comorbidities in vaccinated vs. non-vaccinated participants.
  5. 5Adjusted for age, sex, ethnicity, network, length of time with ESRD, cause of renal failure, comorbidity index, and hospital days.
  6. 6Control group rate available only for one of two studies.
  7. 7RR adjusted in both studies at least for age, sex, and comorbidities.
  8. 8High risk of bias in three of four studies due to inappropriate adjustment for confounders, unclear baseline imbalance, and inappropriate follow-up time.
  9. 9High risk of bias due to inappropriate adjustment for confounders.
  10. 10Significant estimate of effectiveness outside influenza season indicates residual confounding.
  11. 11Adjusted for sex, age, cause of ESRD, vintage, adherence, hospital days, mobility aids, network, comorbidities, and oxygen use.